65,437 trials
Shigellosis
Primary: Number of Participants With Adverse Events — 82; 61; 79; 64 participants
Epilepsy · Partial Seizures
Primary: Change From Baseline in Partial Seizure Frequency Per Week Over the 14-weeks Treatment Period — 43.21 Percent reduction
Urinary Tract Problem
Primary: Smooth cLMA Removal Condition (Score 1) — 86; 40 percentage of participants — p=<0.05
Heart Failure · Ventricular Dysfunction, Left
Primary: Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom…
Cardiovascular Diseases · Atherosclerosis · Myocardial Infarction
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL
Neutropenia
Primary: Blood Neutrophil Counts. — 4.48 10^9 per Liter — p=<0.05
Lung Cancer
Primary: Median Time to Disease Progression — 152 Days
Rosacea
Primary: Mean Change in Number of Inflammatory Lesions From Baseline to Week 12 — .83; -3.13 lesions — p=0.15
Late Infantile Metachromatic Leukodystrophy
Primary: Relative Changes (%) in Gross Motor Function Measurement (GMFM) — -2.98; -5.42; -5.28 Relative % change in total GMFM-88 SOT — p=0.4013
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Head and Neck Neoplasm · Prostatic Neoplasm · Pancreatic Neoplasm
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Attention Deficit Hyperactivity Disorder · INSOMNIA
Primary: Sleep Latency — 34; 34; 32; 34 minutes — p=0.588
Thromboembolism
Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 28; 34; 30 participants — p=0.0002
Obesity · Sarcopenia
Primary: Performance on the 400 Meter Walk — 0.16; 0.02 meters per second — p=<0.05
Rheumatoid Arthritis
Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 52.4 percentage of subjects